Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen, Nagla Karim
{"title":"KRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.","authors":"Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen, Nagla Karim","doi":"10.1093/oncolo/oyaf153","DOIUrl":null,"url":null,"abstract":"<p><p>Non-small cell lung cancer (NSCLC) is among one of the most common and deadliest malignancies worldwide. With this new era of precision medicine, oncogenic driver genes and immunotherapy have changed the way we classify and treat this disease. Among these genes, the Kirsten rat sarcoma virus (KRAS) gene is the most mutated in NSCLC and has been the focus of numerous clinical trials for targeted therapy over the past few years. Here, we present an in-depth literature review of past, present, and future KRAS mutated NSCLC treatment with KRAS inhibitor monotherapy and combinatorial approaches including immunotherapy. The molecular biology behind KRAS targeted therapy is discussed while highlighting the difficulties of KRAS inhibitor treatment, including resistance, and the next steps needed to overcome them.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":"30 6","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12207871/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf153","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Non-small cell lung cancer (NSCLC) is among one of the most common and deadliest malignancies worldwide. With this new era of precision medicine, oncogenic driver genes and immunotherapy have changed the way we classify and treat this disease. Among these genes, the Kirsten rat sarcoma virus (KRAS) gene is the most mutated in NSCLC and has been the focus of numerous clinical trials for targeted therapy over the past few years. Here, we present an in-depth literature review of past, present, and future KRAS mutated NSCLC treatment with KRAS inhibitor monotherapy and combinatorial approaches including immunotherapy. The molecular biology behind KRAS targeted therapy is discussed while highlighting the difficulties of KRAS inhibitor treatment, including resistance, and the next steps needed to overcome them.
期刊介绍：
The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
